Innovative Chemistry for Peptide Manufacturing and Analysis (Recorded version)

Speakers-Peptides

OVERVIEW: The last years have witnessed an explosion of the peptide world in terms of being part of the drug market. Thus, over the previous five years (2016-2020), 18 drugs containing peptides have been approved by the US FDA. Besides, several hundred are in clinical phases or advanced preclinical studies. A large number of them contain (multi)disulfide bridges.

From a manufacturing point of view, small and medium-size peptides are prepared by solid-phase peptide synthesis (SPPS) strategies to the detriment of the classical solution chemistry. Large peptides are synthesized by biotechnological approaches, which can also be used for the no so large peptides. As we are talking about active pharmaceutical ingredients, the final purification is vital in all cases.

However, SPPS has some drawbacks, including the excesses of reagents used and the large volumes of solvents required in each synthetic step. In this regard, during the last few years, other technologies have strongly emerged to synthesize small-medium peptides. One of them, it is the so-called Liquid-Phase Peptide Synthesis (LPPS) method. LPPS combines the best features of both the SPPS and of the solution chemistry as well. Thus, the growing peptide is supported on a soluble tag, which facilitates that all reactions are taking place in solution and at the same time the separation of the target peptide after each synthetic step (coupling of protecting group removal).

Another new technology is based into the flow continuous concept, which allows a large reduction of solvent consumptions with an improved product quality through continuous monitoring and control of the production line.

We are happy to combine in this webinar four excellent speakers that will cover these four topics.


Fill in the form and watch the recorded version

Main Sponsor: